BioAtla Inc (NASDAQ: BCAB) on Monday, plunged -6.90% from the previous trading day, before settling in for the closing price of $1.45. Within the past 52 weeks, BCAB’s price has moved between $1.14 and $4.02.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -56.91%. The company achieved an average annual earnings per share of 40.93%. With a float of $39.02 million, this company’s outstanding shares have now reached $48.35 million.
Let’s determine the extent of company efficiency that accounts for 65 employees. In terms of profitability, gross margin is 93.41%, operating margin of -678.7%, and the pretax margin is -643.92%.
BioAtla Inc (BCAB) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of BioAtla Inc is 19.29%, while institutional ownership is 32.74%. The most recent insider transaction that took place on Dec 26 ’23, was worth 9,320. In this transaction Director of this company bought 4,000 shares at a rate of $2.33, taking the stock ownership to the 15,125 shares. Before that another transaction happened on Dec 20 ’23, when Company’s Chief Executive Officer bought 50,000 for $2.14, making the entire transaction worth $106,910. This insider now owns 1,439,283 shares in total.
BioAtla Inc (BCAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 40.93% per share during the next fiscal year.
BioAtla Inc (NASDAQ: BCAB) Trading Performance Indicators
BioAtla Inc (BCAB) is currently performing well based on its current performance indicators. A quick ratio of 3.11 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of BioAtla Inc (BCAB)
Looking closely at BioAtla Inc (NASDAQ: BCAB), its last 5-days average volume was 0.54 million, which is a drop from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 13.48%. Additionally, its Average True Range was 0.15.
During the past 100 days, BioAtla Inc’s (BCAB) raw stochastic average was set at 2.49%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.19% in the past 14 days, which was lower than the 90.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8210, while its 200-day Moving Average is $2.0380. However, in the short run, BioAtla Inc’s stock first resistance to watch stands at $1.4283. Second resistance stands at $1.5067. The third major resistance level sits at $1.5458. If the price goes on to break the first support level at $1.3108, it is likely to go to the next support level at $1.2717. Should the price break the second support level, the third support level stands at $1.1933.
BioAtla Inc (NASDAQ: BCAB) Key Stats
Market capitalization of the company is 66.18 million based on 48,346K outstanding shares. Right now, sales total 0 K and income totals -123,460 K. The company made 11,000 K in profit during its latest quarter, and -10,590 K in sales during its previous quarter.
